Invasive Aspergillosis Clinical Trial
Official title:
Incidence of Invasive Aspergillosis in Allogeneic Stem Cell Transplantation Patients: an Italian Prospective Multicentre Study
Verified date | February 2009 |
Source | Ospedale Santa Croce-Carle Cuneo |
Contact | n/a |
Is FDA regulated | No |
Health authority | Italy: Ethics Committee |
Study type | Observational |
Evaluation of incidence of invasive aspergillosis in patients who have undergone an allogeneic stem cell transplantation, with particular regard to the role of galactomannan assay and of early TC scan in asymptomatic patients.
Status | Active, not recruiting |
Enrollment | 220 |
Est. completion date | December 2009 |
Est. primary completion date | June 2007 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 16 Years and older |
Eligibility |
Inclusion Criteria: - Age > 16 years - Allogeneic HSCT for a haematological disease - Written informed consent to the study Exclusion Criteria: - Pediatric patients |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Italy | Azienda Sanitaria Ospedaliera santa Croce e Carle | Cuneo |
Lead Sponsor | Collaborator |
---|---|
Ospedale Santa Croce-Carle Cuneo |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of invasive aspergillosis | 1 year | No | |
Secondary | Clinical applicability of the EORTC/MSG criteria in a prospective multicenter trial | 1 year | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06028451 -
ManagemEnt of Antifungal Drug in Invasive Aspergillosis:a Real-word Study
|
||
Completed |
NCT00163722 -
A Multicentre Randomised Controlled Trial Comparing Two Strategies for the Diagnosis of Invasive Aspergillosis in High-risk Haematology Patients
|
Phase 3 | |
Completed |
NCT02394483 -
Single Ascending Oral Dose Study of F901318
|
Phase 1 | |
Completed |
NCT01128907 -
Galactomannan Antigen in Bronchoalveolar Lavage in the Diagnosis of Invasive Aspergillosis in Neutropenic Patients
|
N/A | |
Completed |
NCT00404092 -
Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis
|
Phase 2 | |
Recruiting |
NCT01386437 -
Natural History of Individuals With Immune System Problems That Lead to Fungal Infections
|
||
Withdrawn |
NCT02912026 -
Radiolabelled IV and Oral Metabolism Study of F901318
|
Phase 1 | |
Withdrawn |
NCT03076905 -
Pharmacokinetics of IV Formulation
|
Phase 1 | |
Withdrawn |
NCT03095547 -
Drug/Drug Interactions With F901318
|
Phase 1 | |
Completed |
NCT02737371 -
Multiple Ascending Oral Dose Study of F901318 in Healthy Subjects
|
Phase 1 | |
Terminated |
NCT00836875 -
A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children
|
Phase 3 | |
Terminated |
NCT04876716 -
Azole-echinocandin Combination Therapy for Invasive Aspergillosis
|
Phase 3 | |
Recruiting |
NCT05101187 -
Olorofim Aspergillus Infection Study
|
Phase 3 | |
Enrolling by invitation |
NCT02104479 -
Diagnostic Accuracy of Pleural Effusion Aspergillosis Biomarker Testing
|
||
Not yet recruiting |
NCT05707832 -
A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus
|
Phase 3 | |
Recruiting |
NCT06382922 -
Role of Antifungal Prophylaxis in Elderly Patients With Acute Myeloid Leukemia During Consolidation Therapy
|
||
Terminated |
NCT02396225 -
Concentrations of Voriconazole in Blood and BAL-fluid After Inhalation and Oral Administration
|
N/A | |
Recruiting |
NCT00843804 -
Surveillance for Nosocomial Infections in Pediatric Cancer Patients
|
N/A | |
Completed |
NCT00334412 -
COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive Aspergillosis
|
Phase 4 | |
Completed |
NCT04550936 -
Patterns of Real-World Isavuconazole Use - a Study of Patients With Mucormycosis or Invasive Aspergillosis
|